Core Laboratories (Core Laboratories) Cash And Cash Equivalents : $16.3 Mil (As of Mar. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Core Laboratories Cash And Cash Equivalents?

Core Laboratories's quarterly cash and cash equivalents increased from Sep. 2022 ($13.73 Mil) to Dec. 2022 ($15.43 Mil) and increased from Dec. 2022 ($15.43 Mil) to Mar. 2023 ($16.29 Mil).

Core Laboratories's annual cash and cash equivalents increased from Dec. 2020 ($13.81 Mil) to Dec. 2021 ($17.70 Mil) but then declined from Dec. 2021 ($17.70 Mil) to Dec. 2022 ($15.43 Mil).

Core Laboratories Cash And Cash Equivalents Historical Data

The historical data trend for Core Laboratories's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Core Laboratories Cash And Cash Equivalents Chart

Core Laboratories Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

13.12

11.09

13.81

17.70

15.43

Core Laboratories Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash And Cash Equivalents	Get a 7-Day Free Trial															22.04	16.15	13.73	15.43	16.29

Core Laboratories Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Core Laboratories (NYSE:CLB) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Core Laboratories Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Core Laboratories's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Core Laboratories (Core Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Energy » Oil & Gas » Core Laboratories Inc (NYSE:CLB) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

6316 Windfern Road, Houston, TX, USA, 77040

Website

https://www.corelab.com

Core Laboratories is the premier provider of reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

Executives

Katherine Murray	director	6316 WINDFERN ROAD, HOUSTON TX 77040
Mark Damian Tattoli	officer: SVP, Gen Counsel & Secretary	C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040
Kwaku Temeng	director	C/O CORE LABORATORIES LP, 2216 SHERIDAN STREET, HOUSTON TX 77002
Gwendolyn Schreffler	officer: SVP	C/O CORE LABORATORIES LP, 6316 WINDFERN ROAD, HOUSTON TX 77040
Harvey Robert Klingensmith	director	P.O. BOX 131144, HOUSTON TX 77219-1114
Van Dijken Eeuwijk Monique	director	P.O. BOX 129, BILTHOVEN P7 3720 AC
Jan Willem Sodderland	director	DUINDISTEL 89, NOORDWIJK P7 2202 DE
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Lawrence Bruno	officer: President	6316 WINDFERN ROAD, HOUSTON TX 77040
Mark F Elvig	officer: VP, Counsel & Secretary	6316 WINDFERN, HOUSTON TX 77040
Gregory Barry Barnett	director	853 MILWAUKEE STREET, DENVER CO 80206
Kevin Daniels	officer: CAO & Treasurer	6316 WINDFERN ROAD, HOUSTON TX 77040
Michael Straughen	director	68 RUBISLAW DEN NORTH, ABERDEEN X0 AB15 4AN
Martha Z. Carnes	director	6316 WINDFERN ROAD, HOUSTON TX 77040